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The ISSCR has convened a multinational task force to establish international guidelines for the clinical trans-
lation of stemcells and their direct derivatives. The ISSCRTask Force on the Clinical Translation of StemCells
will define the scientific, clinical, regulatory, ethical, and societal issues thatmust be addressed to ensure that
basic stem cell research is responsibly transitioned into appropriate clinical applications for treating patients.
Stem cell research in all forms is proceeding at an exhilarating
pace around the world and holds great long-term promise for
the amelioration of currently intractable diseases and conditions.
So far, stem cell therapy has only been established as a clinical
standard of care for diseases of the blood system. However,
there are a growing number of centers throughout the world
that are testing stem cell interventions and some that are claim-
ing to offer stemcell treatments for a variety of conditionswithout
clear evidence of safety or efficacy. In some cases, large sums of
money are charged. For the successful application of novel stem
cell-based approaches, it will be necessary to define the scien-
tific and clinical advances, as well as the associated regulatory,
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ISSCR: Committee Forumethical, and societal issues, that need to be addressed in order
to deliver treatments safely, effectively, and fairly. Stem cell ap-
plication without such a solid basis not only risks the safety of
the patients but may also lead to major delays in the develop-
ment of clinically useful therapies.
To date, there exists no comprehensive road map to help
guide the international stem cell research community, clinicians,
industry, patient organizations, and other stakeholders who are
committed to advancing the development of stem cell-based
therapies. Now more than ever, a commonly shared set of pro-
fessional guidelines is necessary to ensure that progress in basic
stem cell research is responsibly transitioned into appropriate
clinical applications for treating patients.
To meet this need, the ISSCR has convened a multinational
task force todevelop international guidelines for theclinical trans-
lation of stem cells and their direct derivatives for human therapy.
The ISSCR Task Force on the Clinical Translation of Stem Cells
is comprised of leading researchers, clinicians, ethicists, and
regulatory officials from 13 countries, each of whom bring to
the discussions their unique backgrounds and experiences
(Table 1). Particular strength is brought by individuals with prior
experience in trials of gene therapy and other innovative clinical
therapies, expertise in preclinical animalmodels, extensive expe-
rience in the regulatory aspects of translational medicine, and
knowledge of the ethical and policy issues pertinent to the imple-
mentation of new therapy. The task force, cochaired by Drs. Olle
Lindvall and Insoo Hyun, will address the wide range of scientific,
clinical, societal, regulatory, and ethical issues pertinent to the
development of stem cell-based therapies through four working
groups: the Quality Control and Manufacturing Subcommittee,
chaired by Dr. Mahendra Rao; the Preclinical Testing Sub-
committee, chaired by Dr. Giulio Cossu; the Clinical Trials Sub-
committee, headed by Dr. Ira Fox; and the Social Justice
Subcommittee, chaired by Dr. Laurie Zoloth.
The ISSCR Task Force convened as a group for the first time
in November 2007 and will work diligently over the course of
2008 via international conference calls and face-to-face meet-
ings. The task force plans to release a draft of their guidelines
and recommendations for public comment in association with140 Cell Stem Cell 2, February 2008 ª2008 ISSCRthe 6th ISSCR Annual Meeting in Philadelphia, June 11–14,
2008. Following a solicitation of comment, the task force will
then produce a final draft of the guidelines by the end of the
year. Throughout the entire process, we invite those interested
to visit the ISSCR website for more information or with sugges-
tions and comments (http://www.isscr.org/clinical_trans).
We thank the members of the task force and other advisors
who are volunteering their time, energy, and experience to the
development of this important set of guiding principles.
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